NCT04501406View on ClinicalTrials.gov

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

PHASE2RecruitingINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Type 2 Diabetes Mellitus (T2DM)Nonalcoholic Steatohepatitis
Interventions
DRUG

Pioglitazone

An insulin-sensitizer FDA-approved to treat hyperglycemia caused by type 2 diabetes.

OTHER

Placebo

Placebo looks just like pioglitazone and is given in the same way but has no active drug in it.

Trial Locations (1)

32610

RECRUITING

University of Florida, Gainesville

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Florida

OTHER